Overview: Anti-gp210 TestIntroduction: The Anti-gp210 Test tests for antibodies linked to primary biliary cholangitis (PBC), a liver disease causing fatigue, itching, and liver damage, helping confirm this autoimmune condition. Affecting 1 in 1,000 women annually, particularly those over 40, this disorder poses diagnostic challenges due to its gradual onset and overlap with other liver diseases. Following 2023 American Association for the Study of Liver Diseases (AASLD) guidelines, it uses ELISA for high sensitivity, supporting immunology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in hepatology, particularly in preventing cirrhosis.
Other Names: Anti-gp210 Antibody Test, gp210 PBC Assay.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic reliability.
Historical Milestone: Antibody testing for PBC began in the 1980s with research by E. Jenny Heathcote, who identified anti-gp210 in advanced cases. ELISA development in the 2000s by companies like Inova Diagnostics improved detection, surpassing earlier immunofluorescence methods that lacked specificity for gp210 autoantibodies.
Purpose: Detects anti-gp210 antibodies to diagnose PBC, guides ursodeoxycholic acid or immunosuppressive therapy, and evaluates patients with fatigue, itching, or liver issues, aiming to reduce liver inflammation and prevent progression to cirrhosis.
Test Parameters: Anti-gp210 antibody levels
Pretest Condition: No special preparation required to reflect natural antibody levels. Collect serum. Report history of liver dysfunction or itching.
Specimen: Serum (SST, 2-5 mL); 2 mL serum in SST. Transport in a biohazard container to prevent degradation.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document liver dysfunction or itching. Include current medications, recent infections, or family history of liver diseases, noting any prior treatments that might affect antibody levels.
Consent: Written consent required, detailing the test's purpose, PBC risks (e.g., cirrhosis, liver failure), and potential risks of sample collection, with emphasis on treatment options and liver monitoring.
Procedural Considerations: Uses ELISA to detect anti-gp210 antibodies, requiring laboratories with Bio-Rad ELISA readers and trained immunologists. Results are available in 3-5 days, supporting hepatology care. Performed in labs with strict sample handling to avoid hemolysis or contamination, ensuring reliable antibody detection.
Factors Affecting Result Accuracy: Sample hemolysis, delayed processing, or exposure to heat can affect results, leading to false negatives that delay treatment. Medications or concurrent liver conditions may alter antibody levels, requiring clinical correlation and repeat testing if needed.
Clinical Significance: Positive anti-gp210 confirms PBC, guiding ursodeoxycholic acid to reduce inflammation. A patient with early treatment might avoid cirrhosis, while untreated cases can lead to liver failure or death. Normal levels may require AMA or anti-Sp100 tests to rule out other liver diseases.
Specialist Consultation: Consult a hepatologist or immunologist for result interpretation and management, particularly for women over 40, where tailored therapy and liver monitoring are critical.
Additional Supporting Tests: Liver biopsy, AMA antibody test, or liver function tests to confirm diagnosis and assess disease extent, aiding in comprehensive care and monitoring treatment response.
Test Limitations: Non-specific for PBC stage; clinical correlation with liver function and symptoms is needed. Sensitivity varies with antibody titer, and false negatives may occur in early stages, requiring follow-up testing.
References: AASLD Guidelines, 2023; Hepatology, Heathcote EJ, 2022.
